Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lowered its stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 5.1% in the second quarter, HoldingsChannel reports. The fund owned 1,827,648 shares of the medical instruments supplier’s stock after selling 98,678 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Harvard Bioscience were worth $5,209,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of HBIO. Allspring Global Investments Holdings LLC acquired a new position in Harvard Bioscience during the second quarter worth approximately $31,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Harvard Bioscience during the 1st quarter valued at $54,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Harvard Bioscience during the 1st quarter worth $112,000. Rhumbline Advisers raised its position in shares of Harvard Bioscience by 24.9% in the 2nd quarter. Rhumbline Advisers now owns 47,753 shares of the medical instruments supplier’s stock worth $136,000 after buying an additional 9,512 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in Harvard Bioscience by 38.7% in the first quarter. BNP Paribas Financial Markets now owns 75,970 shares of the medical instruments supplier’s stock valued at $322,000 after acquiring an additional 21,183 shares during the last quarter. 80.87% of the stock is currently owned by hedge funds and other institutional investors.

Harvard Bioscience Price Performance

HBIO stock opened at $2.37 on Thursday. The company has a market cap of $102.93 million, a PE ratio of -11.95 and a beta of 1.29. The company has a current ratio of 2.05, a quick ratio of 0.94 and a debt-to-equity ratio of 0.48. The stock has a 50-day moving average price of $2.81 and a two-hundred day moving average price of $3.22. Harvard Bioscience, Inc. has a 12-month low of $2.35 and a 12-month high of $5.56.

Harvard Bioscience (NASDAQ:HBIO) last issued its earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.06). The firm had revenue of $23.10 million for the quarter, compared to analysts’ expectations of $29.91 million. Harvard Bioscience had a negative return on equity of 2.70% and a negative net margin of 10.56%. As a group, research analysts predict that Harvard Bioscience, Inc. will post 0.11 EPS for the current year.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.